Literature DB >> 8971164

Rapid proliferation of B cells from adenoids in response to Epstein-Barr virus infection.

R Zeidler1, P Meissner, G Eissner, S Lazis, W Hammerschmidt.   

Abstract

EBV is a human tumor virus that is associated with different types of tumors. A unique feature of EBV is its capability to infect and immortalize human B cells both in vivo and in vitro. In cell culture, this progress is termed immortalization and infected B cells grow out to permanent, so-called lymphoblastoid cell lines. During our experiments, we observed that B lymphocytes derived from adenoids are infected efficiently by EBV and proliferate much more rapidly than any other known type of B cell. High concentrations of adhesion molecules and of CD21, the EBV receptor, present on these cells may account for this phenomenon. Adenoid B cells may therefore represent a particular subpopulation of preactivated B lymphocytes that can greatly simplify and enhance the production of lymphoblastoid cell lines for, e.g., antigen-presenting cells for gene therapeutic approaches and similar applications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971164

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands.

Authors:  A Janz; M Oezel; C Kurzeder; J Mautner; D Pich; M Kost; W Hammerschmidt; H J Delecluse
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  A first-generation packaging cell line for Epstein-Barr virus-derived vectors.

Authors:  H J Delecluse; D Pich; T Hilsendegen; C Baum; W Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

4.  Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus.

Authors:  A Schepers; M Ritzi; K Bousset; E Kremmer; J L Yates; J Harwood; J F Diffley; W Hammerschmidt
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

5.  The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold.

Authors:  Sibille Humme; Gilbert Reisbach; Regina Feederle; Henri-Jacques Delecluse; Kristine Bousset; Wolfgang Hammerschmidt; Aloys Schepers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-28       Impact factor: 11.205

6.  Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells.

Authors:  H J Delecluse; T Hilsendegen; D Pich; R Zeidler; W Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

7.  Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.

Authors:  Martin Schlee; Tanja Krug; Olivier Gires; Reinhard Zeidler; Wolfgang Hammerschmidt; Reinhard Mailhammer; Gerhard Laux; Guido Sauer; Josip Lovric; Georg W Bornkamm
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  The Epstein-Barr Virus Oncogene EBNA1 Suppresses Natural Killer Cell Responses and Apoptosis Early after Infection of Peripheral B Cells.

Authors:  Danielle Westhoff Smith; Adityarup Chakravorty; Mitch Hayes; Wolfgang Hammerschmidt; Bill Sugden
Journal:  mBio       Date:  2021-11-16       Impact factor: 7.867

Review 9.  It Takes Two to Tango: A Review of Oncogenic Virus and Host Microbiome Associated Inflammation in Head and Neck Cancer.

Authors:  Mallory G McKeon; Jean-Nicolas Gallant; Young J Kim; Suman R Das
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.